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Abstract
Background: This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and
progression-free survival rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin
chemoradiotherapy followed by carboplatin and 5-fluorouracil.
Methods: A prospective study of fifty patients diagnosed with locally advanced nasopharyngeal carcinoma
received conventional radiation therapy with a total dose of 6600-7000 cGy in 6-7 weeks and concurrent
chemotherapy of three cycles of carboplatin during radiotherapy, followed by adjuvant chemotherapy using
carboplatin plus 5-fluorouracil for two cycles.
Results: Weight loss and mucositis were the two most common acute major grades 3-4 toxicities (42%).
Myelosuppression occurred subsequently, including leukopenia (30%), neutropenia (20%), anemia (12%), and
thrombocytopenia (6%). Only 8% of patients developed grades 3-4 nausea and vomiting. No patients had renal
and electrolyte abnormalities. Regarding the response evaluation, 100% of patients achieved an objective response
rate of the primary tumor (92% complete response, and 8% partial response). Similarly, all patients also achieved an
objective response rate of the neck node (64% complete response and 36% partial response). The 3-year overall
survival rate and progression-free survival rate were 89.7% and 72.7%, respectively.
Conclusions: Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5- fluorouracil could be
considered as an alternative regimen for locally advanced nasopharyngeal carcinoma patients pertaining to a good
overall response rate, 3-year overall survival and progression-free survival rate with good tolerability.
Introduction
Nasopharyngeal carcinoma is a common head and neck
cancer in Southeast Asia. The incidence is high in the
third to fifth decade of life with a male predominance
[1]. In Songklanagarind Hospital, there were approxi-
mately 80-100 new cases per year. Most of the patients
were diagnosed in the advanced stage of the disease
(60-70%).
According to the good response of radiotherapy
(radiosensitive tumor) and anatomic restrictions, the
standard treatment for nasopharyngeal carcinoma is
definitive radiotherapy. However, 70% of patients pre-
sented with locally advanced stage cancer at the first
time of diagnosis [2-5]. Moreover, it has been reported
that nasopharyngeal carcinoma demonstrated the high-
est incidence of distant metastasis among all head and
neck cancers [6-9]. The benefits of chemotherapy given
concurrently with radiation are supported by the present
data showing improvement in the effects of radiation
through volume reduction, increased radiosensitizing
effect, reduction of micro-metastasis, and overall survi-
val improvement [10-12]. The first study was reported
by the Head and Neck Intergroup 0099, using concur-
rent chemoradiotherapy with three cycles of cisplatin
chemotherapy, followed by a 3-cycles combination of
cisplatin and 5-fluorouracil chemotherapy. The results
showed a significant benefit in both a progression-free
survival and overall survival improvement [13]. Subse-
quently, there were several studies using the same com-
bination of cisplatin and 5-fluorouracil chemotherapy as
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carcinoma, and switching from cisplatin to carboplatin
whenever the patients developed renal or serious toxici-
ties from cisplatin [1,13-18]. Additionally,t h e r ew e r e
some studies using carboplatin as the first-line drug and
the results showed no significant differences in the over-
a l lr e s p o n s er a t ea n do v e r a l ls u r v i v a lr a t ew h e nc o m -
pared to cisplatin [19-21].
Regarding toxicity profiles, carboplatin has less adverse
events in terms of nausea, vomiting, renal toxicity and
ototoxicity, but it does have a more myelosuppressive
effect when compared with cisplatin. There is also no
need for fluid hydration for carboplatin administration,
thus the total infusion time is significantly shorter
resulting in being a good choice of chemotherapy parti-
cularly in an outpatient setting.
Based upon the previous data, the objective of this
study is to evaluate the benefit of carboplatin chemother-
apy on response rate, 3-year overall survival rate, 3-year
progression-free survival rate, including toxicity as a
first-line treatment in combination with radiotherapy in
patients with locally advanced nasopharyngeal carcinoma.
Materials and methods
1) Patients
Fifty patients diagnosed with locally advanced nasophar-
yngeal carcinoma who received concurrent chemora-
diotherapy during May 2005 to December 2007 at
Songklanagarind Hospital were evaluated. Eligible
patients were those with histologically confirmed naso-
pharyngeal carcinoma with at least T3 or N1 ≥ 3c mo r
≥ N2 as classified by the 6
th edition of the American
Joint Committee on Cancer Staging System, and Eastern
Cooperative Oncology Group (ECOG) performance sta-
tus 0-2. The exclusion criteria included patients who
were more than 65 years of age, patients previously
receiving treatment for a locally advanced disease, recur-
rent or metastatic disease, inadequate hematological
profiles (absolute neutrophil count < 1500/mm
3 or pla-
telet count < 100,000/mm
3), serum creatinine > 3 mg/
dL, and poor compliance.
2) Study Procedure
All patients were evaluated by Head and Neck oncolo-
gist including complete history and physical examina-
tion, rigid nasopharyngoscopy, complete blood count,
renal function, electrolyte and liver function tests. Radi-
ological investigations included chest radiography and
computed tomography or magnetic resonance imaging.
An ultrasound of the hepatobiliary system was per-
formed if there was a high level of serum alkaline phos-
phatase. This protocol was approved by the institutional
ethics committees of Songklanagarind Hospital. All
patients provided written informed consent.
Conventional radiation therapy was used in all
patients by 200 cGy per fraction with five daily fractions
per week to a total dose of 6600-7000 cGy. A concur-
rent chemotherapy regimen was given by medical oncol-
ogist using carboplatin (AUC 6) intravenously every 3
weeks for 3 cycles during radiotherapy, followed by 2
cycles more of chemotherapy using carboplatin (AUC 5)
plus 5- fluorouracil (1,000 mg per m
2 per day by 4 days
infusion) every 3 weeks. The treatment protocol was
shown in Figure 1. Dose modifications were performed
according to patient’s toxicity grading. Subsequent doses
of chemotherapy were reduced by 20% if the patients
developed grade 3 or 4 adverse events.
Patient’s toxicities were graded by the Radiation Ther-
apy Oncology Group toxicity criteria during treatment.
The assessment of the tumor response was performed 3
weeks after the last cycle of adjuvant chemotherapy was
completed including a complete physical examination,
rigid nasopharyngoscopy and computed tomography or
magnetic resonance imaging according to the Response
Evaluation Criteria In Solid Tumor (RECIST) criteria.
Patients were followed up every 2 months in the first
year, every 3 months in the second year, every 4 months
in the third year and then every 6-12 months until
death. The treatment of a residual tumor was performed
based upon the guidelines of our hospital.
Statistical Analysis
In the statistical analysis, the epidemiology, clinical char-
acteristics, and outcome data were assessed using the
Fisher’s exact test and the estimated survival probability
was assessed with the Kaplan-Meier method by the R
software package Epicalc.
Results
Fifty patients diagnosed with locally advanced nasophar-
yngeal carcinoma were included in this study. All
patients received concurrent chemoradiotherapy with a
carboplatin agent.
The mean age of the patients was 44 years with a
range of 22 to 62 years. The majority of patients were
male (68%), AJCC stage III and IV (92%), and WHO
histopathology type 1 (52%). Regarding cancer risk
factors, only 16% of patients had a significant family
history of cancer, however 50% of patients were active
smokers and 44% were alcohol consumers. Most
patients had an excellent ECOG performance status
before treatment. Ninety-eight percent of patients
could receive a completion of 5 planned cycles of
chemotherapy. (Table 1)
The most common symptom was a neck mass (82%).
The other subsequent complaints included aural fullness
(62%), nasal obstruction (42%), epistaxis (16%) and
bloody sputum (14%).
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two common moderate to severe acute toxicities that
was found in this protocol. Severity of mucositis was
demonstrated in Figure 2 and 3. Myelosuppression
occurred subsequently, including leukopenia (30%), neu-
tropenia (20%), anemia (12%) and thrombocytopenia
(6%). Only 8% of patients had moderate to severe
nausea and vomiting and no patients had renal or elec-
trolyte abnormalities from this treatment. (Table 2)
Regarding the response evaluation, both the primary
site and neck node had achieved an objective response
rate of 100%. The primary site showed a 92% complete
response and partial response was 8%. Sixty-four percent
of neck node sites showed a complete response and 36%
Figure 1 Treatment protocol of concurrent chemoradiation.
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gressive disease. (Table 3)
The median follow-up time was 37.3 months (range 3-
59 months). (The 3-year overall survival rate and pro-
gression-free survival rate were 89.7% and 72.7%, respec-
tively. (Figure 4, 5)
Discussion
Nasopharyngeal carcinoma is a common head and neck
cancer in Southeast Asia and more than 70% of patients
presented with locally advanced stage cancer. According
to the complexity of nasopharyngeal cancer treatment as
well as the potential adverse events, a multidisciplinary
approach is essentially encouraged. This requires the
involvement of a head and neck oncologist, radiation
oncologist and medical oncologist to achieve the best
treatment outcome for individual patients. In our prac-
tice, the decision pathway is as shown in Figure 6.
Nowadays, concurrent chemoradiotherapy is the stan-
dard treatment for locally advanced nasopharyngeal car-
cinoma. Cisplatin chemotherapy was widely used as a
first-line agent in combination with radiotherapy for
nasopharyngeal carcinoma, whereas carboplatin would
be considered as the option in case of intolerable side
effects from cisplatin, especially ototoxicity and nephro-
toxicity. Therefore, the objective of this study is to eval-
uate the benefit and safety profiles of carboplatin
Table 1 Patient Characteristics
Characteristics Number of patients (%)
Age 44 (22-62)
Sex
- Male 34 (68%)
- Female 16 (32%)
Family history of cancer
- Yes 8 (16%)
- No 42 (84%)
Active smoking
- Yes 25 (50%)
- No 25 (50%)
Alcohol consumer
- Yes 22 (44%)
- No 28 (56%)
Staging
- Stage IIb 4 (8)
- Stage III 18 (36)
- Stage IVa 19 (38)
- Stage IVb 9 (18)
T stage
- T1 9 (18)
- T2a 3 (6)
- T2b 12 (24)
- T3 7 (14)
- T4 19 (38)
N stage
- N0 2 (4)
- N1 9 (18)
- N2 30 (60)
- N3a 6 (12)
- N3b 3 (6)
Histopathology (WHO)
- Type 1 26 (52)
- Type 2 1 (2)
- Type 3 23 (46)
ECOG performance status
- 0 45 (90)
- 1 2 (4)
- 2 3 (6)
Courses of chemotherapy
- 4 courses 1 (2)
- 5 courses 49 (98)
Figure 2 Grade 1 mucositis, erythematous mucosa.
Figure 3 Grade 3 mucositis, confluent pseudomembanous
mucosa.
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first-line treatment in these patients.
Our study strongly supported that carboplatin che-
motherapy can be considered as a first-line alternative
treatment for locally advanced nasopharyngeal carci-
noma patients or switching treatment in patients who
experienced the intolerable adverse events from cisplatin
chemotherapy. There are many advantages in using car-
boplatin as a treatment in patients with locally advanced
nasopharyngeal carcinoma. Firstly, our study showed
comparable acute major toxicity between carboplatin
and cisplatin chemotherapy, however there were less
nausea, vomiting and renal impairment in favoring car-
boplatin chemotherapy. Mucositis was the most com-
mon acute major toxicity found in our study with 42%
serious adverse events. Previous reports with cisplatin
regimen showed mucositis was the most common acute
major toxicity (61%), subsequently to leukopenia (32%),
anemia (19%), thrombocytopenia (2%), vomiting (18%),
renal impairment (2%) and hyponatremia (2%) [22].
However, thrombocytopenia was found to be more
common in our study (6%). Thus, oncologists should be
aware of this common adverse event and symptomatic
treatment should be adequately offered to patients,
which may eventually have an impact on the patients’
compliance to therapy and their quality of life.
Secondly, our study with a carboplatin regimen
showed good patient’s compliance and tolerability. 98%
of patients could receive a completion of 5 planned
Figure 4 3-year overall survival rate of locally advanced
nasopharyngeal carcinoma patients.
Figure 5 3-year progression-free survival rate of locally
advanced nasopharyngeal carcinoma patients.
Table 2 Acute major toxicity profiles (N = 50)
Toxicity Grading (No. (%))
Grade 1-2 Grade 3-4
(Mild) (Moderate to severe)
Hematologic toxicity
Anemia 44 (88) 6 (12)
Thrombocytopenia 30 (60) 3 (6)
Leukopenia 31 (62) 15 (30)
Neutropenia 30 (60) 10 (20)
Non-hematologic toxicity
Nausea 35 (70) 4 (8)
Vomiting 31 (62) 4 (8)
Mucositis 29 (58) 21 (42)
Fatigue 41 (82) 8 (16)
Weight loss 29 (58) 21 (42)
Skin 46 (92) 4 (8)
Hypokalaemia 29 (58) 0 (0)
Hyponatremia 15 (30) 0 (0)
Renal toxicity 2 (4) 0 (0)
Table 3 Response evaluation after complete treatment
Response evaluation Number of patients (%)
Primary
- Complete response 47 (94)
- Partial response 3 (6)
Neck node
- Complete response 32 (64)
- Partial response 18 (36)
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another report which showed that the carboplatin regi-
men had a better tolerability than the cisplatin regimen
[21]. Moreover, the carboplatin regimen took less time
for chemotherapy infusion as there was no pre and post
hydration. As a result, carboplatin could be considered
the better option for outpatient cases.
Subsequently, carboplatin chemotherapy also demon-
strated a comparable response rate to cisplatin. Data from
previous literature on concurrent chemoradiotherapy with
Figure 6 Decision pathway for nasopharyngeal carcinoma patients.
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responses between 49% to 98% [13,17,23-25]. In our study,
t h eo b j e c t i v er e s p o n s er a t eo fb o t ht h ep r i m a r ys i t ea n d
neck node showed 100%, however the complete response
rate of the primary site was 92% and neck node site with a
complete response showed only 64%. As such, carboplatin
could be the acceptable alternative agent used for the
treatment of nasopharyngeal carcinoma.
Finally, our data indicated a good overall survival and
progression-free survival rate from concurrent che-
motherapy with carboplatin chemotherapy with no sub-
stantially difference from cisplatin. The three-year
overall survival rate and progression-free survival rate in
nasopharyngeal carcinoma patients who received con-
current chemoradiotherapy with cisplatin were 71-89%,
and 54-88%, respectively [10,17,21]. These were similar
to our results showing 89.7% of a 3-year overall survival
rate and 72.7% of a 3-year progression-free survival rate.
Similarly, the recent data supported the benefit of carbo-
platin chemotherapy revealing no difference in the over-
all survival rate and progression-free survival rate
between cisplatin and carbplatin chemotherapy given
concurrently with radiation [21].
On the other hand, the nasopharyngeal carcinoma
patients who had a residual neck node after treatment
had to have performed salvage neck dissection according
to the guidelines. However, there were some patients
who needed to have their neck nodes observed and it
was found that their neck nodes had subsided when fol-
low up imaging was done 3-6 months later. Therefore,
it may be that tumor evaluation should be extended to
more than 3 weeks after the complete adjuvant che-
motherapy for the actually tumor response or more
accurate imaging such as PET-CT should be considered
to decrease the likelihood of an unnecessary neck
dissection.
In summary, our data strongly supported the benefit
of concurrent carboplatin chemotherapy with radiother-
apy for locally advanced nasopharyngeal carcinoma
patients pertaining to a good overall response rate, 3-
year over all survival and progression-free survival rate
with good tolerability. It can be considered as an alter-
native first line optional therapeutic regimen for this
patient group.
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